Heterocyclic Compounds as CDK9 Inhibitors: Structural Diversity, Mechanism of Action, and Therapeutic Potential in Cancer and Beyond

被引：0
|
作者：
Bose, Kuntal [1 ]
Shajahan, Afiya [1 ]
Sreekumar, Nandana [1 ]
Aneesh, T. P. [1 ]
机构：
[1] Amrita Vishwa Vidyapeetham, Amrita Sch Pharm, Dept Pharmaceut Chem, AIMS Hlth Sci Campus, Kochi 682041, Kerala, India
来源：
CHEMISTRY & BIODIVERSITY | 2025年 / 22卷 / 01期
关键词：
CDK-9; P-TEFb; RNA polymerase-II; CTD; DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; R-ROSCOVITINE; PHASE-I; ANTITUMOR-ACTIVITY; TARGETING CDK9; DISCOVERY; FLAVOPIRIDOL; APOPTOSIS; COMBINATION;
D O I：
10.1002/cbdv.202401797
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cyclin-dependent kinases (CDKs) are crucial proteins involved in key cellular processes, such as cell division and transcription. Their dysregulation plays a significant role in cancer development. Inhibiting cyclin-dependent kinase 9 (CDK9) impacts several survival pathways in cancer cells, presenting a promising therapeutic approach for various cancers. CDK9, in association with cyclin T1, forms the positive transcription elongation factor b (P-TEFb) complex, which phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II). This phosphorylation promotes the transition from transcription initiation to elongation. This review examines recent advancements in CDK9 modulators, with a particular emphasis on compounds currently in clinical trials.
引用
收藏
页数：16
相关论文
共 50 条
  • [31] Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer
    Wang, Wen-Jing
    Gao, Lixin
    Wang, Simei
    Huang, Wensi
    Meng, Xin-Yu
    Hu, Hao
    Chen, Ziqiang
    Sun, Jingya
    Yuan, Yali
    Zhou, Yubo
    Diao, Xingxing
    Huang, Ruimin
    Li, Jia
    Chen, Xiao-Hua
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (12) : 10035 - 10056
  • [32] Development of novel CDK9 and CYP3A4 inhibitors for cancer therapy through field and computational approaches
    Alsfouk, Aisha A.
    Faris, Abdelmoujoud
    Cacciatore, Ivana
    Alnajjar, Radwan
    FRONTIERS IN CHEMISTRY, 2024, 12
  • [33] Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro
    Winter, Jean M.
    Mustafa, Ebtihal H.
    Wang, Shudong
    Selth, Luke A.
    Hickey, Theresa E.
    Tilley, Wayne D.
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
    Wang, Yubo
    Wang, Mengmeng
    Ma, Lan
    Zhang, Yan
    Jiao, Yue
    Zhang, Shuxin
    Yang, Yijie
    Li, Jialu
    Wei, Mingming
    Cao, Sheng
    Zhang, Kun
    Liu, Shuangwei
    Yang, Guang
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 2528 - 2550
  • [35] Biomimetic black phosphorus nanosheets codeliver CDK9 and BRD4 inhibitors for gastric cancer targeted therapy
    Zhang, Zhe
    Zhang, Xiaoyi
    Ren, Zhaojun
    Wu, Xiaoliu
    Qiao, Haishi
    Huang, Xin
    Zhao, Wei
    Zhang, Yuanying
    Lou, Kexin
    JOURNAL OF MATERIALS CHEMISTRY B, 2023, 11 (26) : 6131 - 6140
  • [36] CDK9 inhibitors modulate the transcriptional landscape of colorectal cancer to suppress MAPK signaling and synergizes with BRAF inhibitors to treat BRAF-mutant colorectal cancer
    Kuang, Chaoyuan
    Wei, Ning
    Mohammadi, Mahshid
    Bhat, Muzaffer A.
    Li, Terence
    Patil, Priyanka
    Wiltz, Othon
    Huang, Renee
    Ooka, Kohtaro
    Quintal, Melanie
    Chu, Edward
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
    G Polier
    J Ding
    B V Konkimalla
    D Eick
    N Ribeiro
    R Köhler
    M Giaisi
    T Efferth
    L Desaubry
    P H Krammer
    M Li-Weber
    Cell Death & Disease, 2011, 2 : e182 - e182
  • [38] Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
    Polier, G.
    Ding, J.
    Konkimalla, B. V.
    Eick, D.
    Ribeiro, N.
    Koehler, R.
    Giaisi, M.
    Efferth, T.
    Desaubry, L.
    Krammer, P. H.
    Li-Weber, M.
    CELL DEATH & DISEASE, 2011, 2 : e182 - e182
  • [39] Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer
    Crucitta, S.
    Del Re, M.
    Fontana, A.
    Bertolini, I.
    Rofi, E.
    De Angelis, C.
    Diodati, L.
    Cavallero, D.
    Salvadori, B.
    Falcone, A.
    Morganti, R.
    Danesi, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [40] Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer
    Shen, Xuetong
    Gao, Chundi
    Li, Huayao
    Liu, Cun
    Wang, Longyun
    Li, Ye
    Liu, Ruijuan
    Sun, Changgang
    Zhuang, Jing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345